LIVE

SLS

SELLAS Life Sciences Group, Inc.

SLS

NASDAQ·Healthcare·Biotechnology·Mkt cap $2.5B

$14.98

+12.89%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$1.39 - $15.88

P/E

-64.40

Fwd P/E

-47.30

Beta

2.53

Div Yield

0.00%

Avg Vol

8.2M

Shares Out

142.4M

Mkt Cap

$2.5B

Price action

Price chart

Up 525.9% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

4 reasons

  • Proprietary peptide immunotherapy platform targeting validated cancer antigens
  • Strategic partnership with Merck providing development support and credibility
  • Late-stage clinical pipeline with Phase III data potential in high-need indications
  • Focus on combination therapy approaches enhancing efficacy and market potential

Bear Case

1 risk

  • High volatility (beta 2.5). Larger-than-normal price swings expected.

Growth

Revenue decline expected

Phase III trial results for GPS in acute myeloid leukemia expected to drive regulatory approval pathway

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+221.3% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 11, 2026

Q2 26 RECAP

MAY 12, 2026

Reported EPS of -$0.05 vs -$0.06 consensus (+16.7% surprise).

EPS beat +16.7%

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+16.7%

Next: May 11, 2026

Revenue trend · last 8Q

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

Wall Street consensus

1 analyst · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

1

100%

Hold

0%

Sell

0%

Median Price Target

Latest: Maxim Group · Mar 12, 2026

vs Industry

How SLS stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.